Cincinnati, Ohio
Phase 1 cancer trials in Cincinnati, OH
38 Phase 1 cancer studies are recruiting participants at sites in Cincinnati as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Cincinnati at a glance
- 38 studies are recruiting at a site in Cincinnati.
- By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (22).
- By sponsor: industry (30), university, hospital or other (7), government (1).
- By research area: Lymphoma (17), Lung Cancer (9), Breast Cancer (3), Melanoma (3), Pancreatic Cancer (3), Prostate Cancer (3).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Cincinnati
Basic details from each study's public record (the 30 most recently updated of 38). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Aminex Therapeutics, Inc.
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT07287917 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Lung cancer studies recruiting in Cincinnati
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Cincinnati Cancer Center-UC Medical Center
- Registry record
- NCT06287775 · updated
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- TRIANA Biomedicines, Inc.
- Study site
- University of Cincinnati Cancer Center
- Registry record
- NCT07491497 · updated
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study site
- The Christ Hospital Physicians - Mt. Auburn
- Registry record
- NCT06303505 · updated
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- DualityBio Inc.
- Registry record
- NCT05914116 · updated
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Genprex, Inc.
- Study site
- Oncology_Hematology Care Clinical Trials, LLC
- Registry record
- NCT05703971 · updated
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Xencor, Inc.
- Study site
- Xencor Investigative Site
- Registry record
- NCT05433142 · updated
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- Phase 1/2
- Ages 18 to 70
- All sexes
- Sponsor
- Iovance Biotherapeutics, Inc.
- Study site
- University of Cincinnati
- Registry record
- NCT05361174 · updated
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- The Christ Hospital
- Registry record
- NCT06040541 · updated
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Christ Hospital Cancer Center
- Registry record
- NCT05379985 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Prostate cancer studies recruiting in Cincinnati
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Oncology Hematology Care Incorporated
- Registry record
- NCT04221542 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT05519449 · updated
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Oncology Hematology Care Incorporated
- Registry record
- NCT07493512 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Melanoma studies recruiting in Cincinnati
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Phase 1/2
- From 12 months, up to 30 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT04851119 · updated
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Georgiamune Inc
- Study site
- University of Cincinnati Cancer Center
- Registry record
- NCT06425926 · updated
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- University of Cincinnati Cancer Center
- Registry record
- NCT03947385 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Lymphoma studies recruiting in Cincinnati
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT04726241 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Cincinnati Children's Hospital
- Registry record
- NCT06173518 · updated
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Phase 1/2
- From 6 months, up to 30 years
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT05533775 · updated
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Phase 1
- From 24 months, up to 18 years
- All sexes
- Sponsor
- ITM Solucin GmbH
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT06441331 · updated
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Umoja Biopharma
- Study site
- University of Cincinnatti Medical Center
- Registry record
- NCT06528301 · updated
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Phase 1/2
- From 12 months, up to 21 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT04870944 · updated
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- University of Cincinnati (UC) Physicians Company, LLC
- Registry record
- NCT05826535 · updated
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Lomond Therapeutics Holdings, Inc.
- Study site
- University of Cincinnati
- Registry record
- NCT06708897 · updated
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT05131022 · updated
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Early Phase 1
- Ages 1 to 21
- All sexes
- Sponsor
- Nationwide Children's Hospital
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT06333899 · updated
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
- Phase 1/2
- Up to age 21
- All sexes
- Sponsor
- St. Jude Children's Research Hospital
- Study site
- Cincinnati Children's Hospital Medical Center
- Registry record
- NCT04195347 · updated
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Phase 1
- Ages 13 and older
- All sexes
- Sponsor
- Newave Pharmaceutical Inc
- Study sites
- Cincinnati Children's Hospital Medical Center · University of Cincinnati
- Registry record
- NCT04771572 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Cincinnati
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study site
- Oncology Hematology Care Primary
- Registry record
- NCT04657068 · updated
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- University of Cincinnati Medical Center
- Registry record
- NCT06445062 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cincinnati, OH on ClinicalTrials.gov.
Ask about studies near Cincinnati
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
194 studies recruiting across 12 cities.
Columbus
86 studies recruiting.
Cleveland
78 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections